Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2023 Earnings Call Transcript
Syros Pharmaceuticals reported a Q1 2023 EPS of $-0.85, beating expectations of $-1.09. The company highlighted progress in clinical trials for MDS, AML, and APL, including the SELECT-MDS-1 trial's amendment to include overall survival as a key secondary endpoint. Syros anticipates pivotal data from SELECT-MDS-1 in Q3 2024 and remains on track for milestones across its programs. Financials show a net loss of $23.8M, with $166M in cash, expected to fund operations into 2025.
Reference News
Syros Pharmaceuticals reported a Q1 2023 EPS of $-0.85, beating expectations of $-1.09. The company highlighted progress in clinical trials for MDS, AML, and APL, including the SELECT-MDS-1 trial's amendment to include overall survival as a key secondary endpoint. Syros anticipates pivotal data from SELECT-MDS-1 in Q3 2024 and remains on track for milestones across its programs. Financials show a net loss of $23.8M, with $166M in cash, expected to fund operations into 2025.